Expert Interview
A Second View: Discussing the potential of Iovance's TIL therapy, lifileucel, and the results from the Phase 2 study in patients with melanoma presented at the ESMO 2023 conference.
Ticker(s): IOVAInstitution: University of Pittsburgh Medical Center
- Associate professor of medicine in the Division of Hematology/Oncology and the director for the Melanoma and Skin Cancer Program at UPMC Hillman.
- Sees 2000 melanoma patients yearly; 100+ patients with mucosal melanoma. Very familiar with the ESMO data
- Specializes in the management of advanced melanoma and the development of early phase studies to test novel immunotherapeutic approaches to treat advanced cancers.
- Principal Investigator on the "Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma" published in the Journal of Clinical Oncology.
Roughly how many patients do you treat with melanoma? With advanced mucosal melanoma?
Added By: dami_adminCan you discuss your clinical experience and/or thoughts on the potential of TIL therapy?
Added By: dami_adminOn a scale from 1-10 (10 being extremely excited) where would you rank your level of excitement for lifileucel?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
